Access >
- 15.07.2008
- Amsterdam
Agendia and Ferrer announcs exclusive agreement for sales of cancer diagnostic services in four major european markets
AMSTERDAM,
The
Netherlands
and
BARCELONA,
Spain,
July
15,
2008
/
Agendia
BV
and
Ferrer
inCode
today
announced
an
agreement
that
will
give
Ferrer
exclusive
... Read +
- 14.12.2007
- Amsterdam, The Netherlands
Agendia and Ferrer announcs exclusive agreement for sales of cancer diagnostic services in four major european markets
AMSTERDAM,
The
Netherlands
and
BARCELONA,
Spain,
July
15,
2008
/
Agendia
BV
and
Ferrer
inCode
today
announced
an
agreement
that
will
give
Ferrer
exclusive
... Read +
- 29.10.2007
- Amsterdam, The Netherlands
October 29, 2007 - Agendia BV appoints Clinical and Scientific Advisory Board. Six eminent cancer researchers advise Agendia
Amsterdam,
The
Netherlands
October
29,
2007.
Agendia
BV,
a
world
leader
in
the
rapidly
evolving
field
of
cancer
molecular
diagnostics
has
appointed
six
members
to
... Read +
- 25.10.2007
- London
October 25, 2007 - Frost & Sullivan Award Recognizes Agendia BV's Pioneering MammaPrint® in the Biomarker-based Breast Cancer Diagnostics Arena
LONDON--(BUSINESS
WIRE)--The
2007
Frost
&
Sullivan
European
Product
Innovation
Award
in
the
field
of
biomarker-based
breast
cancer
diagnostics
is
presented
to
Netherlands-based
Agendia
BV,
for
... Read +
- 22.10.2007
- Amsterdam, Holanda
October 25, 2007 - Agendia BV announces that its Chief Research Officer Laura van 't Veer has received a 2007 Breast Cancer Research Foundation Award
Amsterdam,
the
Netherlands
October
25th,
2007
Agendia
BV,
a
world
leader
in
the
rapidly
evolving
field
of
cancer
molecular
diagnostics,
announced
today
that
its
... Read +
- 22.08.2007
- Barcelona, Spain
Agendia B.V. and Ferrer in Code, a subsidiary of Ferrer, one of Spains leading pharmaceutical companies, have entered into an exclusive agreement for distribution of the Agendia services MammaPrint and CupPrint in Spain.
MammaPrint
is
a
new
highly
accurate
gene
expression
profiling
test
that
offers
clinicians
a
unique
personalised
prognostic
analysis
to
determine
patient
individual
risk
of
recurrence.
... Read +